Physician profile
Paula C Plummer
NPI 1528158656
$2,342.62
in general payments reported to CMS, 2019-2025
18 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $409 · 2021: $350 · 2022: $419 · 2023: $426 · 2024: $238 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $524.65 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $404.63 | 2019-2023 | Jardiance, Mounjaro |
| Abbott Laboratories | $315.70 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $168.76 | 2019-2021 | |
| Glaxosmithkline, LLC. | $156.66 | 2020-2023 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $122.54 | 2025 | Inspire |
| Novo Nordisk INC | $122.46 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $105.00 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $96.91 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $94.48 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $56.98 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.33 | 2020-2021 | |
| Amgen INC. | $40.90 | 2023-2024 | Otezla, Repatha |
| Mayne Pharma Commercial LLC | $22.59 | 2022 | |
| Astellas Pharma US INC | $21.46 | 2023 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $15.27 | 2023 | Accrufer |
| Amarin Pharma, INC. | $14.81 | 2019 | |
| Lumenis, INC | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.